Table 3.

Comparison of Diagnostic Testing in Immunocompromised and Nonimmunocompromised Patients With Central Nervous System Histoplasmosis

Diagnostic testImmunocompromisedNonimmunocompromisedP Value
Culture5/23 (21.7)4/24 (16.7).9484
Antigen22/25 (88)17/25 (64).0978
ID or CF antibody8/21 (38.1)14/22 (63.6).0716
EIA IgG or IgM antibody15/22 (68.2)22/23 (95.7).0430
Antigen or antibody EIA23/25 (92)25/25 (100).4750
Antigen or antibody ID or CF19/20 (95)20/22 (90.9).9326
Diagnostic testImmunocompromisedNonimmunocompromisedP Value
Culture5/23 (21.7)4/24 (16.7).9484
Antigen22/25 (88)17/25 (64).0978
ID or CF antibody8/21 (38.1)14/22 (63.6).0716
EIA IgG or IgM antibody15/22 (68.2)22/23 (95.7).0430
Antigen or antibody EIA23/25 (92)25/25 (100).4750
Antigen or antibody ID or CF19/20 (95)20/22 (90.9).9326

Abbreviations: CF, complement fixation; EIA, enzyme immunoassay; ID, immunodiffusion; IgG, immunoglobulin G; IgM, immunoglobulin M.

Table 3.

Comparison of Diagnostic Testing in Immunocompromised and Nonimmunocompromised Patients With Central Nervous System Histoplasmosis

Diagnostic testImmunocompromisedNonimmunocompromisedP Value
Culture5/23 (21.7)4/24 (16.7).9484
Antigen22/25 (88)17/25 (64).0978
ID or CF antibody8/21 (38.1)14/22 (63.6).0716
EIA IgG or IgM antibody15/22 (68.2)22/23 (95.7).0430
Antigen or antibody EIA23/25 (92)25/25 (100).4750
Antigen or antibody ID or CF19/20 (95)20/22 (90.9).9326
Diagnostic testImmunocompromisedNonimmunocompromisedP Value
Culture5/23 (21.7)4/24 (16.7).9484
Antigen22/25 (88)17/25 (64).0978
ID or CF antibody8/21 (38.1)14/22 (63.6).0716
EIA IgG or IgM antibody15/22 (68.2)22/23 (95.7).0430
Antigen or antibody EIA23/25 (92)25/25 (100).4750
Antigen or antibody ID or CF19/20 (95)20/22 (90.9).9326

Abbreviations: CF, complement fixation; EIA, enzyme immunoassay; ID, immunodiffusion; IgG, immunoglobulin G; IgM, immunoglobulin M.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close